Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases by Bruno Cutuli et al.
Cutuli et al. Radiation Oncology  (2015) 10:110 
DOI 10.1186/s13014-015-0379-7RESEARCH Open AccessLobular carcinoma in situ (LCIS) of the breast:
is long-term outcome similar to ductal carcinoma
in situ (DCIS)? Analysis of 200 cases
Bruno Cutuli1*, Brigitte De Lafontan2, Youlia Kirova3, Hugues Auvray4, Agnes Tallet5, Sandrine Avigdor6,
Claire Brunaud7 and Catherine Delva8Abstract
Background: Lobular carcinomas in situ (LCIS) represent 1-2% of all breast cancers. Both significance and treatment
remain widely debated, as well as the possible similarities with DCIS.
Materials and methods: Two hundred patients with pure LCIS were retrospectively analyzed in seven centres
from 1990 to 2008. Median age was 52 years; 176 patients underwent breast-conserving surgery (BCS) and 24
mastectomy. Seventeen patients received whole breast irradiation (WBRT) after BCS and 20 hormonal treatment
(15 by tamoxifen).
Results: With a 144-month median follow-up (FU), there were no local recurrences (LR) among 24 patients treated
by mastectomy. With the same FU, 3 late LR out of 17 (17%) occurred in patients treated by BCS and WBRT
(with no LR at 10 years). Among 159 patients treated by BCS alone, 20 developed LR (13%), but with only a
72-month FU (17.5% at 10 years). No specific LR risk factors were identified. Three patients developed metastases, two
after invasive LR; 22 patients (11%) developed contralateral BC (59% invasive) and another five had second cancer.
Conclusions: LCIS is not always an indolent disease. The long-term outcome is quite similar to most ductal carcinomas
in situ (DCIS). The main problems are the accuracy of pathological definition and a clear identification of more aggressive
subtypes, in order to avoid further invasive LR. BCS + WBRT should be discussed in some selected cases, and the
long-term results seem comparable to DCIS.
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surgeryBackground
Firstly described in 1941 by Muir, Foote and Stewart, the
exact significance of lobular carcinoma in situ (LCIS),
also called lobular neoplasia (LN), remains debated,
ranging for many years from a simple marker of
subsequent invasive carcinoma to, more recently, a real
pre-cancerous lesion in many cases, especially invasive
lobular carcinoma (ILC) [1,2].
The variability of pathological definitions according to
time, with frequent combined analysis of LCIS/LN and
atypical lobular hyperplasia (ALH) or new classification
defined in 2002 and including three types of lobular* Correspondence: bcutuli@iccreims.fr
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unless otherwise stated.intra-neoplasia (LIN), as well as rarity and frequent
insufficient long-term follow-up in several series, all
represent additional uncertainties regarding its optimal
treatment [3].
Our study evaluated the long-term outcome in a cohort
of 200 women with pure LCIS treated by three different
options, i.e. breast-conserving surgery alone (BCS), BCS
with whole breast irradiation (BCS +WBRT) or mastectomy
(M). We compared our results according to the same treat-
ments used in DCIS [4,5], particularly assessing the poten-
tially life-threatening risk of invasive local recurrence (LR).Materials and methods
From January 1990 to December 2008, 200 patients with
“pure” LCIS (without associated DCIS and/or previousThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer) were retrospectively collected in seven centres,
also sometimes including benign lesions, e.g. atypical
(ductal and/or lobular) hyperplasia or sclerosing adenosis.
Seven patients had bilateral synchronous LCIS. Median
age was 52 years (range: 32–77).
79 out of 180 (44%) patients were post-menopausal
and 45 of them (57%) underwent hormonal replacement
therapy (HRT) for a 5-year median duration (76% by
estrogen and progestins association).
In 60 out of 166 (30%) specified cases, a first and/or
second family-history degree of breast cancer was found.
Two patients had BRCA-1 and 2 mutation.
53 (44%) patients underwent previous surgery for a
benign lesion, i.e. fibroadenoma (14), cyst (8), atypical
hyperplasia (8) and sclerosing adenosis (2). There
were 95 (46%) lesions in the right and 112 (54%) in
the left breasts, respectively. Clinical symptoms were
present in 44 (21%) cases. In 143 (72%) cases, LCIS was
discovered by mammography and/or ultrasound (Table 1).
In 15 cases, the lesion was discovered incidentally after
surgery performed for benign disease or breast reduction.
Treatments
Surgery
168 patients underwent lumpectomy (7 with a complemen-
tary resection), 8 quadrantectomy and 24 (6 in two times)
mastectomy (nine of whom had contralateral prophylactic
mastectomy), due to multicentric disease or patient's
preference.
Radiotherapy
Seventeen patients underwent a classical 50 Gy/25 fractions
WBRT, including 8 with a 10-Gy boost. There were no
factors influencing the WBRTchoice, i.e. age, LIN subtype,
excision quality or multifocality.
Hormonal therapy (HT)
Twenty patients received hormonal therapy (15 by
Tamoxifen), 17 of them after BCS (10.7%), two after
BCS + RT (11.8%) and only one after mastectomy. HTTable 1 Radiological features leading to biopsy
(183 evaluable cases)
n %
Microcalcifications (isolated) 105 57.4
Microcalcifications and other abnormalities 15 8.1
Round opacity 31 16.9
Stellar opacity 6 3.3
Abnormal density 12 6.6
Architectural distorsion 4 2.1
No abnormalities 10 5.6was significantly more prescribed in case of incomplete
excision (16% versus 4.5%, p = 0.041) or LIN 3 or 2 versus
1 (43%, 15% and 4% respectively, p = 0.03).
Pathology
All centres had pathologists deeply involved in the breast
field, but central review could not be carried out. The
subtype was only specified in 128 cases (classical in 124
and pleomorphic in 4).
According to LIN classification (applied since 2002),
among our 94 evaluable cases, we found 25 LIN 1, 54
LIN 2 and 15 LIN 3. Moreover, among 172 evaluable
cases, a single focus of LCIS was found in 101 patients
(59%) and multiple foci in 71 (41%). The multiple foci rate
was significantly higher (p = 0.001) in patients treated by
mastectomy (77.3%) versus BCS (+/−WBRT) (36%). Among
143 evaluable cases, excision was considered complete in
112 (78%) cases, incomplete in 13 (9%) and doubtful in 18
(13%). Among 75 evaluable cases, the median lesion size
was 12 mm.
Moreover, associated atypical epithelial hyperplasia
(AEH), atypical lobular hyperplasia (ALH) and sclerosing
adenosis were found in 68/187 (36%), 48/184 (26%) and
46/181 (25%) of the cases respectively.
Results
Local recurrences
All patients had a bi-annual clinical FU in the first five
years, then once a year. A mammography was also
completed by ultrasound each year. With a 144-month
median follow-up, there were no local recurrences (LR)
among 24 patients who underwent mastectomy. With the
same follow-up, three out of 17 (17%) patients treated by
BCS + RT developed LR (all of them after 10 years), i.e.
one DCIS, one infiltrating ductal carcinoma (IDC) SBR-1
pT1bN0 and one IDC SBR-3 pT1cN1. Among the BCS
group with only a 72-month follow-up, 20/159 (13%) LR
occurred (Figure 1). Sixteen (67%) were invasive, including
11 IDC, two tubular carcinomas and three ILC (one had
previously recurred as LCIS). Among non-invasive LR,
there were three DCIS and one mixed DCIS-LCIS.
There were no significant clinical (mode of discovery, age)
or pathological (number of foci, excision quality, AH
presence) LR factors.
Axillary recurrences
An associated axillary nodal involvement (ANI) was
found in three cases (two ILC and one IDC). One
patient treated by mastectomy developed axillary
recurrence 20 years later certainly due to missed foci
of invasive carcinoma in the mastectomy specimen. Thus,
the overall axillary recurrence rate for the entire cohort
was 2% (4/200).
Figure 1 LCIS: Local recurrence incidence.
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Three patients developed metastases, two with previous
invasive LR (one ILC and one IDC). Thus, the rate of
metastasis after invasive LR was 11% (2/18).
Contralateral breast cancer (CBC)
Twenty-two out of 191 patients developed CBC (11.5%)
(Figure 2). The rate varies according to treatment and
follow-up (Table 2). Overall, 13 out of 22 (59%) CBC
were invasive.
Second cancers
Five patients developed a second cancer (colon: 2,
thyroid: 1, skin and salivary gland: one each).
Long-term follow-up
Six patients were lost of follow-up and 189 are still alive.
Four patients died, one by BC, one by intercurrent
disease and two by colic cancer.
Discussion
Incidence and epidemiology
Due in large part to increased mammographic screening,
DCIS incidence increased 7.2 fold in the USA from 1980
to 2001 and LCIS 2.6 fold [6,7]. Similar trends were
observed in other Western countries [8]. The median
age at diagnosis in most LCIS series varies from 45
to 50 years [1,8], i.e. 7–8 years younger than in the DCIS
series [5]. Few data suggest a possible LCIS increase dueto hormone replacement therapy (HRT) [6]. In our series,
57% of 79 menopausal women received HRT. Despite the
possible discovery by clinical symptoms, very often due to
benign associated lesions (cyst or fibroadenoma), our
series confirms that about 65% of LCIS were discovered
by clustered microcalcifications, such as reported by other
studies [9,10]. From a pathological point of view, the
distinction between LCIS and ALH is sometimes difficult
and subjctive. Both lesions are often associated [11-13]
and finally represent a temporal continuum in which
the extent of lobular involvement varies [1]. Moreover, the
loss of E-cadherin expression characterizes LCIS, facilitating
a distinction from ductal lesions.
Significance of LCIS and possible underestimation at
core-needle biopsy (CNB)
For many years, LCIS (only representing 1-2% of all
breast cancers) has just been considered a marker of risk
for subsequent (in situ or invasive) cancer in both
breasts [1]. The discovery by mammography or presence
of another benign lesion leads to a complementary excision
after CNB only in a variable part of cases, ranging from
40% to 70% in the literature and without clear selec-
tion criteria. Some authors proposed surveillance or
complementary excision according to several and often
different parametres, sometimes including «lobular
neoplasia» encompassing both LCIS and ALH. In a large
review by Hussain [2], including 31 studies, 789 out of
1229 (64%) patients diagnosed with LN on CNB had
Figure 2 LCIS: Contralateral breast cancer incidence.
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pleomorphic LCIS (PLCIS) and 246 unspecified LN. In
this review, the overall underdiagnosis rate.
(DCIS and/or invasive BC at subsequent excision)
was 27% (211 out of 789). In a wide series from New
York, among 201 out of 285 (71%) excisions per-
formed for LN after CNB, 26 (13%) were upgraded; 7
had DCIS, 9 ILC and 10 IDC [14]. However, the risk
of underestimated malignancy at subsequent excision
(DCIS or infiltrating carcinoma) was only 8% (DCIS:
2.7% and infiltrating BC: 5.3%) among 478 lesions in
a literature review reported by Murray, but with wide
variations (from 3% to 35%) [15]. Finally, the initial
underestimation risk after CNB showing LCIS or ALH is
quite difficult to assess, without clear predictive criteria in
the literature [16].Table 2 Contralateral breast cancer (CBC) according to
treatment
n FU* % In situ (n) Invasive (n)
BCS** (159) 15 72 9 4 10
BCS +WBRT*** (17) 3 144 17 3 -
Mastectomy (24) 5 144 21 2 3
Total (200) 22 87 11 9 13
*months.
**BCS: breast-conserving surgery.
***WBRT: whole breast irradiation.Potential risk of LCIS invasiveness
Such as for DCIS, the potential LCIS risk is invasive BC
development, keeping in mind that both lesions are theoret-
ically initially fully curable. Compared to women in the
general population, those with LCIS have a minimum 5–6
fold higher risk of IBC [9]. This risk increases in case of
associated lesions (AH) [10] and especially when first-
degree family history of BC was present [2], almost reaching
the risk (8–10 fold) of women with BRCA 1–2 mutations.
These data confirm the crucial importance of identifying
the most «aggressive» LCIS subtypes leading to invasive BC.
Comparisons between DCIS and LCIS treatments
DCIS now represent 15 to 20% of all breast cancers
(63 000 cases in the USA in 2014) and are considered
long-term precursors of invasive BC in 40-50% of the
cases, even in low-grade lesions [5]. However, DCIS
encompass several heterogeneous lesions due to many
biological and molecular features leading to variable
progressions to invasion. There are much more DCIS
treatment data than for LCIS [13,17,18].
Mastectomy remains performed in 30-42% of DCIS
according to the series [19,20], due to extension of the
lesions, multicentricity and/or patients' preference. The
local control rate was about 98% [4]. On the other hand,
very few data are available on mastectomy rate in LCIS
[7,13]. In our series, multicentricity seemed to be a factor
leading to mastectomy.
Table 4 Comparison between DCIS and LCIS (data
adapted from references 1, 2, 5, 9, 13, 17, 36, 37)
DCIS (%) LCIS (%)
Frequency 15-20 1-3
Calcifications at diagnosis 90 60-70
Excision rate after CNB 100 50-80




BCS +WBRT 60-70 1-3
CBC 5-8 12-15
10-year LR (after BCS) 15-30 10-15
Invasive LR 50-60 30-40
BCS: breast conserving surgery, with wide variations in extent. CNB: core
needle biopsy. CBC: contralateral breast cancer. LR: local recurrence (in situ
and/or invasive). WBRT: whole breast irradiation.
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Epidemiology and End Results (SEER) database, among
11 641 patients diagnosed with LCIS from 2000 to 2009,
16% underwent mastectomy, but with large differences
based on geographic areas and age (from 12% to 24%)
[7]. The local control rate, such as in our 24 patients,
was almost 100%.
Due to more frequent discovevry of «small lesions», a
conservative approach was gradually used in DCIS
[17,18]. The standard treatment includes BCS and whole
breast irradiation (WBRT) according to four large ran-
domized trials (combined in a meta-analysis including
over 4 500 cases) and retrospective studies showing that
WBRT halfed the local recurrence rates (LR), both in situ
and invasive [21-25]. Consequently, for these lesions, the
10-year LR rates are about 5-8% in the most recent series
[26-28], reaching only 1% at 7 years in the very selected
study on low-risk DCIS by RTOG [29]. However, in
20-25% of the cases, for various reasons, WBRT is
not used in DCIS, leading, even in very selected cases
(small lesions, wide margins, low grade), to a 15-20%
10-year LR rate, half of which invasive [30,31].
This is a crucial problem, because now several studies
confirm the unfavourable impact of invasive LR in patients
treated for DCIS with a 12-18% long-term of metastatic
evolution [21,22,32]. For LCIS, there are no clear thera-
peutic guidelines, both after CNB and surgical excision
[1,2,9]. The previously SEER-quoted study [7] showed that
10% of the patients had biopsy alone (precise criteria for
the choice not specified) and 73% excision alone, whereas
only 1% (116 patients) underwent complementary WBRT,
without specific choice criteria or data on local control.
Table 3 shows the risk of subsequent invasive or in situ
carcinoma after treatment of LCIS by excision alone in
the main literature series [33-36]. This risk is quite similar
in several DCIS series with the same treatment, i.e.
San Francisco or Ontario series [30,31], as well as a
very selected study by ECOG [37], with approximately
50% of invasive local recurrences.
In comparison with DCIS, the slope of the LR curve
for LCIS seems quite less sharp and more spread out in
time (see Figure 1), suggesting that the overall cancerizationTable 3 Risk of subsequent invasive or in situ carcinoma
after treatment of LCIS by excision alone
Author (year) Ref n FU** Invasive BC DCIS
Total % Total %
Salvadori (1991) [33] 78 58 5 6,4 - -
Ottesen (1993) [34] 69 61 8 11,6 4 5,8
Fisher E. (2004) [35] 180 144 9 5 17 9,4
Chuba (2005) [36] 3141* 120 NS 8,8 NS NS
*SEER data.
**months.process was slower.The increase of local recurrence rates
due to young age and incomplete excision (close and/or
positive margins) is not clearly documented in LCIS
compared to DCIS. However, few LCIS subtypes, e.g.
pleomorphic LCIS, very extensive LCIS (with over ten
involved acini) or LCIS with a great amount of necroses,
seem to be clearly more aggressive lesions [3,9] and should
be treated such as DCIS, as suggested by 2009 French
Breast Carcinoma in Situ guidelines (www.e-cancer.fr).
Therefore, in these aggressive LCIS, WBRT addition
should be discussed in the multidisciplinary team, in
order to minimize the LR risk. In our previous report,
we observed only one invasive LR out of 25 cases, with a
153-month follow-up [38]. In the present study, the LR
is slightly higher (3/17), but the number of cases is lower
and all LR occurred beyond 10 years.
These results are quite similar to DCIS treated by
lumpectomy and WBRT in the series with a more than
120-month follow-up, both in retrospective studies and
randomized trials [5,21-23]. However, it remains difficult
to better identify the «aggressive» LCIS subtypes. A recent
study by the Curie Insitute showed that KI67 should be
used as a «discriminant» parameter to select more aggres-
sive LCIS. Indeed, among 43 patients, the 5-year LR rates
were 1/34 (3%) for low Ki 67 (≤10%) and 3/9 (33%) for
high Ki 67 (>10%) (p = 0.0054) [39].
Another possible way of reducing the long-term risk
of LR is the use of Tamoxifen. Indeed, the positivity rate
of ER and/or PgR in LCIS is higher than in DCIS [9],
and the results of the former NSABP P-1 prevention
study showed that the most effective reduction of invasive
BC by tamoxifen was observed among women with LCIS
and ALH, suggesting a possible increased impact of
anti-estrogens in the first steps of breast cancerization
[40]. Similar results were observed in the NSABP P-2
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other hand, it should be remembered that the CBC
rate in LCIS is quite higher than in DCIS, reaching
14% at 10 years in a large study from Connecticut
tumor registry [42]. Consequently, the use of tamoxifen
should be considered, especially in pre-menopausal women
with a lower incidence of thrombo-embolic accidents and
uterine cancers.
In short, LCIS is not always an indolent disease.
Table 4 shows several features in comparison with DCIS.
In fact, many data are quite similar with the almost
same long-term LR rates, both after BCS alone and
BCS +WBRT.The scarcity of this lesion urgently requires
further larger studies, at least prospective long-term
records, to clearly assess the LR and CBC rates according
to radiological, clinical, histopathological and molecular
features, in order to evaluate the potential benefit in
selected cases of WBRT and tamoxifen [43].
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